


BAY-826

Cat. No.:	HY-100756		
CAS No.:	1448316-08-2		
Molecular Formula:	C ₂₆ H ₁₉ F ₅ N ₆ OS		
Molecular Weight:	558.53		
Target:	Discoidin Domain Receptor; Tie		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (179.04 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		1.7904 mL	8.9521 mL	17.9041 mL
		5 mM		0.3581 mL	1.7904 mL	3.5808 mL
10 mM			0.1790 mL	0.8952 mL	1.7904 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (1.79 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1 mg/mL (1.79 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1 mg/mL (1.79 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	BAY-826 is a selective and potent TIE-2 inhibitor with a K _d of 1.6 nM, respectively.
IC₅₀ & Target	Tie2 1.6 nM (K _d)
In Vitro	BAY-826 is a selective and potent inhibitor of TIE-2 (dissociation constant = 1.6 nM) and binds with similar high affinity to only 4 of 456 tested kinases, namely, TIE-1, DDR1, DDR2, and Serine/threonine-protein kinase 10 (LOK) (dissociation

constant = 0.9, 0.4, 1.3, and 5.9 nM). The high biochemical affinity for TIE-2 translates into very potent cellular mechanistic activity with an EC₅₀ of about 1.3 nM for inhibition of TIE-2 autophosphorylation in human umbilical vein endothelial cells. The TIE-2 inhibitor BAY-826 is tested for its acute growth inhibitory as well as anti-clonogenic properties in all four mouse glioma cell lines. BAY-826 is highly selective against other angiogenic kinases, such as VEGFR, fibroblast growth factor receptor (FGFR), or Platelet-derived growth factor receptor (PDGFR), and affects VEGF-stimulated proliferation of HUVEC only at μ M concentrations, respectively.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BAY-826 (oral gavage; 25 mg/kg, 50 mg/kg, 100 mg/kg) potently inhibits ANG-1-stimulated TIE-2 autophosphorylation in murine lungs in female CB17/scid mice^[1].

BAY-826 improves tumor control in syngeneic mouse glioma models. Co-treatment with BAY-826 and irradiation is ineffective in one model (SMA-497), but provided synergistic prolongation of survival in another (SMA-560) cell. TIE-2 inhibition may improve tumor response to treatment in highly vascularized tumors such as glioblastoma^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay

Murine SMA-497, SMA-540, SMA-560, and GL-261 glioma cells are used. The cells are commonly cultured as adherent monolayers in Dulbecco's modified Eagle medium supplemented with 10% heat-inactivated fetal calf serum and 2 mM glutamine. Cells are irradiated in a Co radiation source at 1, 3, and 9 Gy. The cells are pre-incubated for 10 min in the 37°C incubator either with 0.1% DMSO as control or 1 μ M BAY-826. TIE-2 autophosphorylation is induced for 20 min with either 4 mM Na₃VO₄ or with 400 ng/mL COMP-ANG-1 in the presence of either 0.1% DMSO or 1 μ M BAY-826^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration

Following anesthesia, a burr hole is drilled in the skull 2 mm lateral to the bregma. The needle of a Hamilton syringe is introduced to a depth of 3 mm. A volume of 2 μ L of a single cell suspension in PBS is slowly injected into the right striatum. In female and male VM/Dk mice (in-house husbandry) 5 \times 10³ SMA glioma cells are implanted, whereas in female C57Bl/6 mice (Charles River) 2 \times 10⁴ GL-261 cells are implanted (n = 10 per group). The mice employed have body weights > 20 g. Systemic treatment with BAY-826 is performed by oral gavage (100 mg/kg body weight daily) or the solvent (10% Ethanol/40% Solutol/50% Aqua dest), respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Schneider H, et al. J Neurochem. 2017 Jan; 140(1):170-182. doi: 10.1111/jnc.13877. Epub 2016 Dec 12. Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA